Allogen Biotech receive €50k from H2020 SME Instrument Phase 1 Funding
Allogen Biotech’s ARM-B project has been partly funded under the H220 SME Instrument Phase 1 by the European Commission. The funding includes €50,000 for business and technical feasibility. It is the intention of Allogen Biotech to apply for a Phase 2 grant in the region of €1,000,000 to aid in the full commercialisation of ARM-B and bring it to market.
ARM-B (Allergy Registration Microarray Biosensor) represents a leap in allergy diagnostics since "skin prick" tests. The test is performed either by a clinician or at home. The user places a patch, containing a micro-needle array onto their skin. Each micro-needle represents a single allergen. The detection processes involves measuring an immunoresponse from the user’s skin. This response is digitised and analysed using a reader or Smartphone.
ARM-B is a follow-on product from Allogen Biotech's allergen detection technology. It exploits significant intellectual property developed by Allogen Biotech in the fields of rapid diagnostics and electrochemistry.
"Skin Prick" allergy testing is regarded as the most reliable method for allergy diagnosis. The test involves a medical professional placing a small droplet of allergen on the skin and then penetrating the skin so the allergen has a chance to create an immunoresponse. This triggers a localised swelling or hive which is measured to give an allergy severity rating. A major drawback to Skin Prick is time constraint and number of allergens to be tested. ARM-B involves a single-stage patch placement and can detect hundreds of allergens in a matter of minutes.
The ARM-B skin-allergy diagnostics patch is a compact, easy to apply, low-cost allergy testing product. It can provide allergy information in an electronic format. It is highly sensitive (capable of detecting a mild allergic reaction) and offers reliable identification of a wide panel of allergic disorders in a single test.
The worldwide market for allergy diagnostics and therapeutic products and services is over US$25.7bn (2014). The projection for diagnostic tests is set to reach US$5.74bn by 2022, with a rate of growth of 10.5% (CAGR) over a five-year period. Europe leads the market (volume/value) in terms of its use of allergy diagnostics products, constituting just over 50% of this diagnostics sector. US are the second-largest global market and show the highest rate of growth due to the increasing prevalence of inhaled allergies: rates driven by rising incidences of allergic diseases thought to be caused by lifestyle choices and environmental impacts.
Much of this value and growth is accounted by skin allergy tests (CAGR 8.2%, 2023), where consultation costs is typically $200 to $300, compared to antibody blood test $500 to $1000. Allogen Biotech’s technical expertise in biosensor development for diagnostics and commercial understanding of the allergy test market positions the company uniquely to exploit the technological advances ARM-B offers.
Allogen Biotech nominated for 7 Intellectual Property Awards
Allogen Biotech have been nominated for 7 awards at the Intellectual Property Awards 2014. We have been nominated for Designer of the Year, Inventor of the Year, Branded Goods IP Award, IP R&D - Indigenous Award, IP R&D Collaboration of the Year, Tech IP Award and Tech Transfer of the Year. The winners will be announced at the DoubleTree by Hilton Dublin, Burlington Road, Dublin 4 on Thursday, 2nd October 2014.
Allogen Biotech featured in Irish Examiner
Adapting sensors that were previously used in medical diagnostics, Allogen Biotech has created a unique device which can be used to check gluten levels during food production, writes Trish Dromey.
Ben speaks to allaboutbusiness.ie
Allogen Biotech CEO Ben Teeling recently spoke to allaboutbusiness.ie, and talked about the difficulty in starting up your own business and what winning the Grand Prix in the 2013 Startup awards has meant to both himself and the business.
Private Investment and Innovative HPSU Fund
Allogen Biotech successfully completed its first round of fundraising on the 15th of January 2014. This money was raised between private investors and Enterprise Ireland through the Innovative High Potential Start Up Fund.
The Innovative High Potential Start Up Fund was established in order to support the start-up and development costs of High Potential Start Up Companies. This fund is perfect for companies developing and commersialising new or substantially improved technologies in comparison to state-of-the-art industry players in the european Union and global marketplace.
Contract Work & Sample Preparation
Allogen Biotech has contracted ITT Dublin and MiCRA for a major research project that will be an integral part of our product. This project commenced on the 6th of January 2014 will run for 6 months during 2014. This project combined with the previous two projects will form the foundation of our final product.
Allogen Biotech has also begun work on improving the sample preparation process for these test. This project is a continuation from the research project toward the development of an efficient method for gluten extraction carried out in conjunction with ITT Dublin during the summer.
Allogen Biotech has purchased a Leapfrog Creatr 3D Printer to be used for prototyping and product development. This new piece of technology will enhance Allogen's in house product development. The Creatr is designed with a dual extruder and is one of the most competitive and durable 3D printer on the market. The Creatr offers the largest build sizes in the price category of fully assembled qualitative 3D printers. The sturdy frame adds to the durability of the 3D printer, providing you a product that lasts.
Completed Sample Preparation Project
Allogen Biotech completed a research project on the development of an efficient method for gluten extract on the 29th of August 2013. This project was funded through an Enterprise Ireland Co-Funded Innovation Voucher partnering with IT-Tallaght and MiCRA. The project was a great success and this research will be used in our final product.
Startup Awards 2013
Allogen Biotech won four awards at the Startup Awards 2013 in the Royal Hibernian Academy.
Allogen Biotech won Food & Drink Entrepreneurial Startup of the Year, Product Startup of the Year, Startup Business Plan of the Year and the Grand Prix.
We would like to thank Startups Ireland, Vodafone IE Business, Independent, Sage Ireland and Bord Bia for the awards.
High Potential Start Up Showcase: Class of 2012
Allogen Biotech is developing a device that will enable food manufacturers check, quantify, and manage levels of allergens or contaminants in their product.
Allogen Biotech's mission is to provide manufacturers with the ability to inspect their products for potential allergens, in a quick, easy to interpret and reasonably priced way, via a portable handheld device.
Testing of foods to control levels of unwanted ingredients or contaminants is becoming commonplace among food manufacturers and food processors.
With the increase in food-borne illnesses from contaminated food, governments and food manufacturers alike are striving to produce safer foods. In the US alone, food-related illnesses affect an estimated seventy-six million people annually.
Allogen Biotech has identified a breakthrough in this area of food contamination testing. Using sensors that are primarily developed for the medical diagnostic industry, Allogen Biotech is developing a "point of testing" device.
Startup of the day: Allogen Biotech
Today’s startup is Allogen Biotech, which is developing a new food contaminant testing system by applying sensor technology normally used in medical diagnostics to the food industry.
Company: Allogen Biotech
Founders: Ben Teeling and Derek Graydon
Support: Enterprise Ireland
What it does: food contamination testing technology
Biggest lesson learned: “Listen to advice, especially from people who have been down a similar road.”
Over the past few weeks, the scandal involving horsemeat found in beef burgers has left many people wondering exactly what is in their food. Food producers are required to test products for contamination, which can prove to be a costly and time consuming issue.
Coupled with the rise in foods free from substances such as gluten, the testing process has become a big issue for many producers. A new Dublin-based startup aims to ease the burden on food producers by developing a hand-held testing device that could save both time and money.
New innovator: Allogen Biotech
Food contamination testing can be a time consuming and costly process for food producers sending samples away for analysis. But that could change with a new testing product being developed by biomedical engineers Ben Teeling and Derek Graydon of Allogen Biotech.
The partners hit on applying the sensor technology normally used in medical diagnostics to the food industry and have come up with a hand-held device that can test for contaminants accurately and quickly on site.
“From our market research we identified an opportunity in the wider food manufacturing and processing industries for a portable food contamination testing device that used biosensors rather than traditional testing methods,” Ben Teeling says.
Allogen Biotech awarded Highly Commended Award
Allogen Biotech received a "Highly Commended Award" from Intertrade Ireland. A panel which consisted of independent entrepreneurs, investors and experts evaluated Allogen Biotech's business plan as part of the Seedcorn Competition which is the largest business competition for early stage / high growth companies in any sector in Ireland.
The Business Plan focuses on developing a device for the purpose testing food to control levels of unwanted ingredients or contaminants for food manufacturers and food processors. With the increase in food borne illnesses from contaminated food, governments and food manufacturers alike are striving to produce safer foods.
Allogen Biotech awarded Competitive Start Fund
After submitting an application to Enterprise Ireland’s Competitive Start Fund, Allogen Biotech was short listed and invited to pitch in front of Enterprise Ireland senior staff, and invited guests.
Allogen Biotech was successful in its attempt to secure equity investment. The basis of the investment was a cash sale of 10% of the company for €50,000.
Completed “Proof of Principal” technical study
Allogen Biotech undertook a Proof of Principal technical study with the help of MiCRA and the Institute of Technology Tallaght. The aim of the study was to determine whether proposed technology platforms were suitable for Allogen Biotech’s product needs.
The outcome of the study was very positive and pushed Allogen Biotech in a more focused market area and a technical development path.
Synergy Enterprise Platform Completion
Ben and Derek took part in the Synergy Enterprise Platform Program, a scheme funded under Enterprise Ireland to develop a business concept into a viable, and investable business plan.
As part of the program, there was up-skilling of general business tools such as accounting, legal, and presentation skills. There was also exposure to Enterprise Ireland staff, business advisors and consultants, and preparation for VC and state bodies introduction and investment pitching.